A PYY compound which is capable of binding to the human Y2 receptor comprising i) tryptophan at the position corresponding to position 30 of hPYY, ii) N(alpha)-methyl-L-arginine at a position corresponding to position 35 of hPYY, iii) lysine at a position corresponding to position 7 of hPYY and a modifying group attached to the epsilon amino group of said lysine, wherein said modifying group is defined by A-B-C-, wherein A- is selected from wherein a is an integer from 12 to 19, b is an integer from 10 to 16, and c is an integer from 10 to 16, and wherein * denotes the attachment point to -B-, wherein B- is selected from wherein d is 1 or 2; e is 1 or 2; and f is 2, 3 or 4; and wherein *** denotes the attachment point to A-, and ** denotes the attachment point to -C-, wherein -C- is or wherein g is an integer in the range of 1-5, h is an integer in the range of 1-5, i is an integer in the range of 2 to 6, j is an integer in the range of 1 to 6, and wherein **** denotes the attachment point to -B-, and ***** denotes the attachment point to the epsilon amino group of the lysine residue in the position corresponding to position 7 of hPYY, and a maximum of 8 amino acid modifications as compared to hPYY, or a pharmaceutically acceptable salt thereof. i) tryptophan at the position corresponding to position 30 of hPYY, ii) N(alpha)-methyl-L-arginine at a position corresponding to position 35 of hPYY, iii) lysine at a position corresponding to position 7 of hPYY and a modifying group attached to the epsilon amino group of said lysine, wherein said modifying group is defined by A-B-C-, wherein A- is selected from wherein a is an integer from 12 to 19, b is an integer from 10 to 16, and c is an integer from 10 to 16, and wherein * denotes the attachment point to -B-, wherein B- is selected from wherein d is 1 or 2; e is 1 or 2; and f is 2, 3 or 4; and wherein *** denotes the attachment point to A-, and ** denotes the attachment point to -C-, wherein -C- is or wherein g is an integer in the range of 1-5, h is an integer in the range of 1-5, i is an integer in the range of 2 to 6, j is an integer in the range of 1 to 6, and wherein **** denotes the attachment point to -B-, and ***** denotes the attachment point to the epsilon amino group of the lysine residue in the position corresponding to position 7 of hPYY, and a maximum of 8 amino acid modifications as compared to hPYY, or a pharmaceutically acceptable salt thereof. wherein A- is selected from wherein a is an integer from 12 to 19, b is an integer from 10 to 16, and c is an integer from 10 to 16, and wherein * denotes the attachment point to -B-, wherein B- is selected from wherein d is 1 or 2; e is 1 or 2; and f is 2, 3 or 4; and wherein *** denotes the attachment point to A-, and ** denotes the attachment point to -C-, wherein -C- is or wherein g is an integer in the range of 1-5, h is an integer in the range of 1-5, i is an integer in the range of 2 to 6, j is an integer in the range of 1 to 6, and wherein **** denotes the attachment point to -B-, and ***** denotes the attachment point to the epsilon amino group of the lysine residue in the position corresponding to position 7 of hPYY, and a maximum of 8 amino acid modifications as compared to hPYY, or a pharmaceutically acceptable salt thereof.